A 74-year-old woman with a 39-year history of lupus developed a second autoimmune disease, granulomatosis with polyangiitis (GPA), revealing a surprising overlap between two conditions doctors thought worked differently. This unusual case, published in Internal Medicine, offers new insights into how multiple autoimmune diseases can coexist and what triggers their development. Can Two Autoimmune Diseases Happen at the Same Time? Yes, and this case shows just how complex the immune system can be. The patient had lived with systemic lupus erythematosus (SLE), a condition where the body attacks its own nuclear material, for nearly four decades. Then, she developed GPA, a type of vasculitis where the immune system attacks small blood vessels. While both are autoimmune diseases, they work through different mechanisms, making their overlap unusual and challenging to diagnose. The patient's symptoms included a persistent cough, fever, and fatigue that didn't respond to antibiotics. Doctors discovered lung nodules, sinus inflammation, and kidney problems. Laboratory tests revealed elevated anti-MPO-ANCA antibodies at 182 U/mL, compared to a normal range below 3.5 U/mL. A lung biopsy confirmed the diagnosis by showing necrotizing granulomas and vascular injury consistent with GPA. Why Do Lupus and Vasculitis Sometimes Occur Together? The connection lies in how the immune system handles neutrophil extracellular traps (NETs), which are web-like structures released by immune cells. In lupus patients, research shows that the body struggles to clear these NETs properly. When NETs accumulate, they can contain proteins like proteinase-3 (PR3) and myeloperoxidase (MPO) that trigger the formation of ANCA antibodies, the hallmark of vasculitis. "Although the mechanism of SLE is not fully understood, several studies have reported impaired clearance of neutrophil extracellular traps (NETs) containing PR3 and MPO, leading to small vessel injury. Moreover, excessive or persistent NETs have been linked to ANCA induction. These abnormalities in NET clearance and ANCA induction may offer a plausible mechanistic basis for SLE-AAV overlap syndrome," the study authors explained. How Do Doctors Treat Overlapping Autoimmune Diseases? - High-Dose Corticosteroids: The patient received intravenous methylprednisolone to quickly suppress the aggressive immune response and prevent organ damage. - Oral Maintenance Steroids: Prednisolone was continued to maintain control of both conditions and prevent flares of the underlying lupus. - B-Cell Targeted Therapy: Rituximab, a monoclonal antibody that depletes B cells, was administered to address the autoimmune component and reduce antibody production. The treatment strategy focused on the vasculitis component while monitoring for lupus activity. Seven months after starting therapy, the patient's kidney function improved significantly, with serum creatinine dropping from 1.26 mg/dL to 0.72 mg/dL. Lung nodules and bronchial wall thickening also improved on imaging. This case highlights an important clinical lesson: patients with long-standing lupus who develop new symptoms should be evaluated carefully for secondary autoimmune conditions. The overlap of SLE and GPA is rare, but recognizing it early allows doctors to adjust treatment strategies and prevent serious complications like kidney failure or lung damage. What Does This Mean for Future Autoimmune Disease Research? Beyond this single case, the pharmaceutical industry is advancing treatments that could help patients with multiple autoimmune conditions. Zenas BioPharma is developing obexelimab, a drug that targets CD-19 and FcγRIIb to suppress B cell function. The company reported positive Phase 3 results for immunoglobulin G4-related disease (IgG4-RD), with a 56% reduction in disease flares compared to placebo. The FDA application is expected in the second quarter of 2026, with a Phase 2 trial in lupus patients expected to report results by the end of 2026. Additionally, Zenas is developing orelabrutinib, a drug that penetrates the brain and targets Bruton's tyrosine kinase (BTK), for multiple sclerosis. Phase 3 trials for both primary progressive and secondary progressive forms are underway, with the secondary progressive trial expected to launch in the first quarter of 2026. The convergence of clinical insights from rare cases and emerging therapies suggests that future treatment of autoimmune diseases will become more personalized and targeted, potentially addressing multiple immune pathways simultaneously rather than treating each condition in isolation.
